Publicacións en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (40)

2024

  1. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

2023

  1. Lenalidomide maintenance based on a genetic profile

    Blood

  2. Monoclonal gammopathy of uncertain significance

    Medicina Clinica, Vol. 161, Núm. 5, pp. 217-224

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  3. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

    Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8

  4. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

    Blood cancer journal, Vol. 12, Núm. 2, pp. 32

  5. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  2. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Value in Health, Vol. 23, Núm. 4, pp. 441-450

  3. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

  4. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 34, Núm. 8, pp. 2000-2011

  5. Subcutaneous versus intravenous daratumumab in multiple myeloma – Authors' reply

    The Lancet Haematology

  6. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

    The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

  2. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)

    Leukemia

  3. Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma

    HemaSphere, Vol. 3, Núm. 3

  4. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1